Evidence map›Paper›PMID 41888480›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Mapping individual molecular connectomes in Alzheimer's disease.

Zhilei Xu, Mite Mijalkov, Jiawei Sun, Yu-Wei Chang, Arianna Sala, Giovanni Volpe, Mario Severino, Mattia Veronese, Sara Garcia-Ptacek, Joana B Pereira and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mapping individual molecular connectomes in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhilei XuDepartment of Clinical Neuroscience, Division of Neuro, Karolinska Institutet, Solna, Sweden.ORCID 0000-0002-5155-6346
Mite MijalkovDepartment of Clinical Neuroscience, Division of Neuro, Karolinska Institutet, Solna, Sweden.
Jiawei SunDepartment of Clinical Neuroscience, Division of Neuro, Karolinska Institutet, Solna, Sweden.
Yu-Wei ChangDepartment of Physics, University of Gothenburg, Gothenburg, Sweden.
Arianna SalaComa Science Group, GIGA Consciousness, University of Liege, Liege, Belgium.
Giovanni VolpeDepartment of Physics, University of Gothenburg, Gothenburg, Sweden.
Mario SeverinoDepartment of Information Engineering, University of Padua, Padua, Italy.
Mattia VeroneseDepartment of Information Engineering, University of Padua, Padua, Italy.
Sara Garcia-PtacekDepartment of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Joana B PereiraDepartment of Clinical Neuroscience, Division of Neuro, Karolinska Institutet, Solna, Sweden.
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer Foundation AF-1032782Blomquist familyBlomqvist Foundation 2-3980/2025Dementia FoundationEuropean Union - NextGenerationEU and the Romanian GovernmentGamla Tjänarinnor FoundationGun och Bertil Stohnes StiftelseKarolinska Institute Consolidator Position grantKI Consolidator GrantKI FoundationsKing Gustaf V and Queen Victoria's FoundatioKI Research IncubatorKung Gustav:S & Viktorias StiftelseLars Hierta Memorial FoundationNational Institutes of Health GrantOmanian Ministry of Research, Innovation and DigitalizationRomania's National Recovery and Resilience Plan 760250/28.12.2023Romania's National Recovery and Resilience Plan PNRR-C9-I8-CF109/31.07.2023Strategic Research Area NeuroscienceStratNeuroSwedish Alzheimer FoundationSwedish Brain Foundation FO2025-0059Swedish Research Council 2022-01108Swedish Research Council 2025-03210U.S. Department of Defense W81XWH-12-2-0012
6 · The paper itself

Abstract

introductionMapping individual differences is crucial to improve personalized medicine approaches in Alzheimer's disease (AD), which is characterized by strong inter-individual variability in the accumulation patterns of tau and amyloid beta pathology.

methodsWe assess the progression of AD across the disease continuum by building individual molecular connectomes using longitudinal positron emission tomography (PET) data.

resultsWe demonstrate that these connectomes constitute a unique fingerprint, capable of identifying a single individual from a large group of subjects. Alterations in the connectomes discriminate different diagnostic groups and predict cognitive decline to a higher extent than conventional PET measures. We introduce a novel gene-specific transcription network analysis that linked individual tau and amyloid connectomes to a common transcriptomic profile of apoptosis, with the tau connectome being specifically related to pyrimidine metabolism, and the amyloid connectome to histone acetylation. DISCUSSION: Individual molecular connectome mapping provides a novel and sensitive framework to monitor AD progression.

Indexed as

Alzheimer DiseaseBrainConnectomeAmyloid beta-PeptidesDisease ProgressionFemaleHumansMalePositron-Emission Tomographytau ProteinsTranscriptomeAmyloid beta-Peptidestau Proteinsamyloidmolecular connectomepositron emission tomographytautranscriptome

Identifiers

PMID41888480
PMCPMC13093537

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.